TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1467110

Group type: EXPERIMENTAL
Intervention: Interpleural morphine 2.5 mg i.p. and normal saline i.v. (group I)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Morphine 2.5 mg i.v. and i.p. saline (group II)
Number of subjects: 17
Study: 6420025

Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg p.o.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg IM
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg IM preceded by cimetidine 600 mg p.o.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cimetidine 600 mg p.o. and Morphine 10 mg IM
Number of subjects: 8
Study: 29796016

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 141

Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 141

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Social control group
Number of subjects: 141
Study: 28065188

Group type: EXPERIMENTAL
Intervention: Flavanone-rich orange juice (272.1 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Homogenised whole orange (452.8 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Orange juice (128.9 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isoenergetic control (0 mg flavanones)
Number of subjects: 28
Study: 25327311

Group type: EXPERIMENTAL
Intervention: Mitiglinide 10 mg three times a day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sitagliptin 50 mg once a day
Number of subjects: 11
Study: 23566649

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg daily)
Number of subjects: 361
Study: 19931080

Group type: EXPERIMENTAL
Intervention: DRP/20EE
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DRP/20EE plus metformin (1,500 mg/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DRP/20EE plus CPA (12.5 mg/d, 10 days per cycle)
Number of subjects: 48
Study: 18685517

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16630997

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 3029
Study: 12401731

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg b.i.d. orally)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 10216887

Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®) as second-line chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic corticotherapy
Number of subjects: 0
Study: 7565904

Group type: EXPERIMENTAL
Intervention: Oral vitamin K administration (group A)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K administration (group B)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin K administration (group C)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Reference population (children aged 1-15 years)
Number of subjects: 152
Study: 1980827

Group type: EXPERIMENTAL
Intervention: molindone at pre-established doses equivalent to pre-study neuroleptic
Number of subjects: 18

Group type: COMPARATOR
Intervention: haloperidol at pre-established doses equivalent to pre-study neuroleptic
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: molindone at 200% of pre-study dose
Number of subjects: 18

Group type: COMPARATOR
Intervention: haloperidol at 200% of pre-study dose
Number of subjects: 18
Study: 7326693

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 160
Study: 31814531

Group type: EXPERIMENTAL
Intervention: Culturally-relevant, physical activity-enhanced behavioral weight loss intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard behavioral weight loss intervention
Number of subjects: 85
Study: 31532802

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-based cognitive behavioral therapy (ICBT) for 14 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 70
Study: 29273027

Group type: EXPERIMENTAL
Intervention: Citrus bergamia extracts-based formulation (CitriCholess)
Number of subjects: 98
Study: 26281160

Group type: EXPERIMENTAL
Intervention: Liquid probiotic form based on Enterococcus faecium L3, daily dose of 1.5 x 10(9) CFU for three months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no probiotic)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Liquid probiotic form based on Enterococcus faecium L3
Number of subjects: 29
Study: 24806143

Group type: EXPERIMENTAL
Intervention: Modified short-axis out-of-plane (SA-OOP) ultrasound guidance
Number of subjects: 164

Group type: COMPARATOR
Intervention: Long-axis in-plane (LA-IP) ultrasound guidance
Number of subjects: 164
Study: 23095644

Group type: EXPERIMENTAL
Intervention: Intervention targeting frailty
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Intervention and Control
Number of subjects: 119
Study: 19448381

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg twice a day with 20 mg esomeprazole once a day
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo with placebo esomeprazole
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Ibuprofen in ApoE epsilon4 carriers (n=27)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo in ApoE epsilon4 carriers (not specified)
Number of subjects: 132
Study: 17854445

Group type: EXPERIMENTAL
Intervention: SRL+corticosteroids (ST)
Number of subjects: 430

Group type: COMPARATOR
Intervention: SRL+CsA+ST
Number of subjects: 430
Study: 15352910

Group type: EXPERIMENTAL
Intervention: Orlistat treatment for 6 months
Number of subjects: 10
Study: 11585018

Group type: EXPERIMENTAL
Intervention: Mifepristone (single dose) in early luteal phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mifepristone (single dose) in mid-luteal phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mifepristone alone or in combination with a prostaglandin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mifepristone with prostaglandin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mifepristone (emergency contraception)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg vs 10 mg)
Number of subjects: 0
Study: 10463872

Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine eye drops
Number of subjects: 10
Study: 8830063

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Valproate (VPA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 2142576

Group type: EXPERIMENTAL
Intervention: EE/GSD
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EE/DG
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EE/DG and EE/GSD
Number of subjects: 11
Study: 489921

Group type: EXPERIMENTAL
Intervention: Cimetidine 0.75 mg/kg bw
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cimetidine 1.5 mg/kg bw
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cimetidine 3.0 mg/kg bw
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cimetidine 6.0 mg/kg bw
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31972628

Group type: EXPERIMENTAL
Intervention: Trazodone OAD
Number of subjects: 324

Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 324
Study: 31306331

Group type: EXPERIMENTAL
Intervention: Recent reproductive coercion
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Physical or sexual adolescent relationship abuse
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Nonpartner sexual violence
Number of subjects: 550

Group type: COMPARATOR
Intervention: Care-seeking behaviors with recent reproductive coercion
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Testing or treatment for sexually transmitted infections
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Partner age and number of sexual partners
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Hormonal contraception only
Number of subjects: 550
Study: 28090798

Group type: EXPERIMENTAL
Intervention: GTR 20 mg/mL daily
Number of subjects: 729
Study: 25614151

Group type: EXPERIMENTAL
Intervention: Percutaneous laser disc decompression (PLDD)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 115
Study: 23433939

Group type: EXPERIMENTAL
Intervention: DPA meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: EPA meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil meal
Number of subjects: 0
Study: 20945090

Group type: EXPERIMENTAL
Intervention: Sequential decision-making process regarding adjuvant therapy options (one at a time)
Number of subjects: 1781

Group type: COMPARATOR
Intervention: Standard, comprehensive decision process (all at once)
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Sequential decision-making process among higher-numeracy participants
Number of subjects: 1781

Group type: COMPARATOR
Intervention: All options considered simultaneously among lower-numeracy participants
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Sequential decision-making process among lower-numeracy participants
Number of subjects: 1781
Study: 19756164

Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg/day
Number of subjects: 2306

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/day plus HCTZ 12.5 mg/day
Number of subjects: 2306

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/day (open-label)
Number of subjects: 2306
Study: 17143633

Group type: EXPERIMENTAL
Intervention: ACDF with Cloward procedure (CP)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: ACDF with cervical intervertebral fusion cage (CIFC)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: ACDF (both procedures)
Number of subjects: 95
Study: 14667741

Group type: EXPERIMENTAL
Intervention: Immediate colposcopy
Number of subjects: 825

Group type: COMPARATOR
Intervention: Surveillance by repeat HPV testing, cytology, and colposcopy at 12 months
Number of subjects: 825
Study: 10826311

Group type: EXPERIMENTAL
Intervention: Endocrine agents (antiestrogens, progestational drugs, aromatase inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study: 9031926

Group type: EXPERIMENTAL
Intervention: Hysteroscopic surgery (TCRE)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Hysteroscopic surgery (ELA)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 204
Study: 1736566

Group type: EXPERIMENTAL
Intervention: Silent ischemia during exercise test (ET) with ST depression
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Silent ischemia during exercise test (ET)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: ST depression combined with pain at ET
Number of subjects: 740
Study: 6502506

Group type: EXPERIMENTAL
Intervention: Morphine sulfate (10 mg) administered intravenously
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cimetidine (300 mg po four times a day)
Number of subjects: 7
Study: 3943267

Group type: EXPERIMENTAL
Intervention: Metoprolol (12.5, 25, 50, 100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bevantolol (18.75, 37.5, 75, 150 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control observations (no drug)
Number of subjects: 16
Study: 29762276

Group type: EXPERIMENTAL
Intervention: 40 IU injection of Botulinum toxin A (BoNT‐A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A)
Number of subjects: 60
Study: 26908120

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0
Study: 24732441

Group type: EXPERIMENTAL
Intervention: Electronic cigarettes without nicotine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Electronic cigarettes with nicotine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Conventional cigarettes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control session (electronic cigarette without liquid)
Number of subjects: 25
Study: 22612785

Group type: EXPERIMENTAL
Intervention: Locked continuous single-layer sutures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-layer interrupted sutures
Number of subjects: 60
Study: 20074348

Group type: EXPERIMENTAL
Intervention: Quality improvement programme
Number of subjects: 2000

Group type: COMPARATOR
Intervention: No quality improvement programme (Control)
Number of subjects: 2000
Study: 18175773

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 10305
Study: 16343234

Group type: EXPERIMENTAL
Intervention: TEC (paclitaxel 175 mg/m(2) followed by carboplatin AUC 5 with epirubicin 75 mg/m(2))
Number of subjects: 887

Group type: COMPARATOR
Intervention: TC (paclitaxel 175 mg/m(2) followed by carboplatin AUC 5 without epirubicin)
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: TEC (with epirubicin)
Number of subjects: 887

Group type: COMPARATOR
Intervention: TC (without epirubicin)
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 887
Study: 15600131

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation plus cognitive distraction (PMR/CD)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sleep restriction and stimulus control (SR/SC)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Flurazepam (Dalmane) (MED)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE)
Number of subjects: 53
Study: 11195269

Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SSRIs) with daily or intermittent dosing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luteal phase only SSRI administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormonal interventions (suppression of ovulation)
Number of subjects: 0
Study: 9421558

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized clinical trials (RCTs)
Number of subjects: 0
Study: 2064730

Group type: EXPERIMENTAL
Intervention: l-dopa (300-1000 mg per day) with peripheral decarboxylase inhibitor (benserazide, carbidopa)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control persons (n=14, aged 58.0 ± 10.4 years)
Number of subjects: 9
Study: 6199470

Group type: EXPERIMENTAL
Intervention: Cranial irradiation (1,800 rad) with intrathecal methotrexate (RT group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intravenous and intrathecal methotrexate without irradiation (IVIT group)
Number of subjects: 108
Study: 31465533

Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide
Number of subjects: 150
Study: 29162321

Group type: EXPERIMENTAL
Intervention: NFC Pendant
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: NFC Pendant and Voice
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (Sticker)
Number of subjects: 96
Study: 28039406

Group type: EXPERIMENTAL
Intervention: PPB
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PL
Number of subjects: 38

Group type: COMPARATOR
Intervention: CON
Number of subjects: 38
Study: 24267796

Group type: EXPERIMENTAL
Intervention: 5% ALA
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 10% ALA
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 20% ALA
Number of subjects: 110
Study: 22843637

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking programme with two 30-minute physical activity consultations from a trained practice nurse
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group (normal care for 12 weeks)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking programme
Number of subjects: 284
Study: 20716081

Group type: EXPERIMENTAL
Intervention: Midazolam with fentanyl
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ketamine with fentanyl
Number of subjects: 120
Study: 17379489

Group type: EXPERIMENTAL
Intervention: Closeness to death
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Performance status and baseline QoL
Number of subjects: 107
Study: 15665012

Group type: EXPERIMENTAL
Intervention: Asoprisnil 10 mg QD or higher
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Asoprisnil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12164298

Group type: EXPERIMENTAL
Intervention: Dipstick assay for detection of Salmonella typhi-specific IgM antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Culture testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipstick assay for culture-negative patients
Number of subjects: 0
Study: 10564562

Group type: EXPERIMENTAL
Intervention: Becaplermin gel-100 microg/g
Number of subjects: 922

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 922
Study: 8728346

Group type: EXPERIMENTAL
Intervention: Doxazosin 1 mg once daily for 10 days, followed by 2 mg once daily for 5 days (morning administration)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Doxazosin 1 mg once daily for 10 days, followed by 2 mg once daily for 5 days (evening administration)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of morning and evening administration of doxazosin
Number of subjects: 24
Study: 1996576

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD, 0.6 mg/kg/d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal protein diet (NPD, 1.3 mg/kg/d)
Number of subjects: 9
Study: 6481662

Group type: EXPERIMENTAL
Intervention: 10-week aerobic exercise program
Number of subjects: 105

Group type: COMPARATOR
Intervention: Meditation program
Number of subjects: 105

Group type: COMPARATOR
Intervention: Music appreciation program
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Trained subjects in Experiment 1
Number of subjects: 105

Group type: COMPARATOR
Intervention: Untrained subjects in Experiment 1
Number of subjects: 105

Group type: COMPARATOR
Intervention: Training subjects in Experiment 1
Number of subjects: 105
Study: 30664303

Group type: EXPERIMENTAL
Intervention: Topiramate (300 mg/day, titrated over 6 weeks and maintained for 6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study: 30106614

Group type: EXPERIMENTAL
Intervention: Visual aid (flowchart)
Number of subjects: 138

Group type: COMPARATOR
Intervention: No visual aid
Number of subjects: 138
Study: 29298017

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Local collagen treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 63
Study: 24751581

Group type: EXPERIMENTAL
Intervention: 190‐NBI
Number of subjects: 360

Group type: COMPARATOR
Intervention: HD‐WL
Number of subjects: 360
Study: 22017810

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 69
Study: 20668152

Group type: EXPERIMENTAL
Intervention: Internet-based glucose monitoring system (IBGMS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 50
Study: 18317742

Group type: EXPERIMENTAL
Intervention: Glutamate injection (0.1 ml, 0.5 M) into latent MTrPs
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isotonic saline injection (0.1 ml, 0.9%) into latent MTrPs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Glutamate injection into non-MTrPs
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isotonic saline injection into non-MTrPs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Glutamate injection compared to isotonic saline
Number of subjects: 14
Study: 15772059

Group type: EXPERIMENTAL
Intervention: Resistance training (6-month progressive program)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (low-intensity yoga and deep breathing)
Number of subjects: 51
Study: 12466347

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 363

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Serum IGFBP‐1
Number of subjects: 363
Study: 10202876

Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (oral E2, 1 mg daily for 12 months, then 2 mg daily) with 5 or 10 mg of dydrogesterone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study: 7607192

Group type: EXPERIMENTAL
Intervention: Naloxone (N; 1.2 mmol.l‐1; 3 ml)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P; 0.9% saline; 3 ml)
Number of subjects: 9
Study: 1975891

Group type: EXPERIMENTAL
Intervention: 2000 lux artificial full‐spectrum light
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 300 lux artificial full‐spectrum light
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal controls (not exposed to SAD conditions)
Number of subjects: 23
Study: 393356

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg intravenous infusion over 30 minutes)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg orally thrice daily for six days)
Number of subjects: 12
Study: 31843374

Group type: EXPERIMENTAL
Intervention: Naloxone stocked in pharmacies
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Naloxone availability on the day of contact
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Prescription requirement for naloxone
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Identification requirement for naloxone
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Average price of naloxone nasal spray
Number of subjects: 524
Study: 30612327

Group type: EXPERIMENTAL
Intervention: PEEP adapted to achieve the best dynamic lung compliance
Number of subjects: 100

Group type: COMPARATOR
Intervention: PEEP of 10 cm H2O (control group)
Number of subjects: 100
Study: 28328179

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg twice daily
Number of subjects: 1540

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1540
Study: 26010304

Group type: EXPERIMENTAL
Intervention: Matched health messages for non-intenders
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Mismatched health messages for non-intenders
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Matched health messages for intenders
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 205